TY  - JOUR
AU  - Forschner, Andrea
AU  - Kähler, Katharina C
AU  - Gschnell, Martin
AU  - Langan, Ewan A
AU  - Weishaupt, Carsten
AU  - Meiss, Frank
AU  - Thoms, Kai-Martin
AU  - Wahl, Renate U
AU  - Göppner, Daniela
AU  - Garzarolli, Marlene
AU  - Sachse, Michael
AU  - Schlaak, Max
AU  - Reitmajer, Markus
AU  - Kellner, Ivonne
AU  - Gesierich, Anja
AU  - Mohr, Peter
AU  - Meier, Friedegund
AU  - von Wasielewski, Imke
AU  - Herbst, Rudolf
AU  - Utikal, Jochen
AU  - Pföhler, Claudia
AU  - Ulrich, Jens
AU  - Terheyden, Patrick
AU  - Kaatz, Martin
AU  - Haferkamp, Sebastian
AU  - Leiter, Ulrike
AU  - Ugurel, Selma
AU  - Weichenthal, Michael
AU  - Berking, Carola
AU  - Gutzmer, Ralf
AU  - Schadendorf, Dirk
AU  - Nanz, Lena
AU  - Loquai, Carmen
TI  - Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg.
JO  - Frontiers in immunology
VL  - 16
SN  - 1664-3224
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2025-00535
SP  - 1509886
PY  - 2025
AB  - Although systemic therapies have improved considerably over the last decade, up to 50
KW  - Humans
KW  - Melanoma: drug therapy
KW  - Melanoma: mortality
KW  - Melanoma: therapy
KW  - Male
KW  - Female
KW  - Registries
KW  - Skin Neoplasms: drug therapy
KW  - Skin Neoplasms: mortality
KW  - Aged
KW  - Middle Aged
KW  - Prospective Studies
KW  - Aged, 80 and over
KW  - Terminal Care: methods
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Immune Checkpoint Inhibitors: adverse effects
KW  - Adult
KW  - Treatment Outcome
KW  - BRAF and MEK inhibitors (Other)
KW  - end of life (Other)
KW  - immune checkpoint inhibitors (Other)
KW  - ipilimumab (Other)
KW  - melanoma (Other)
KW  - nivolumab (Other)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40066437
C2  - pmc:PMC11891187
DO  - DOI:10.3389/fimmu.2025.1509886
UR  - https://inrepo02.dkfz.de/record/299594
ER  -